Clarity AD: Initial 48-Month Findings From the Open-Label Extension of Lecanemab in Early Alzheimer’s Disease
Nakagawa 2025 IPA JSA Presentation
Clarity AD: Initial 48-Month Findings From the Open-Label Extension of Lecanemab in Early Alzheimer’s Disease
